Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 10/20 | 0.44 |
| ▸ | PPARG | P37231 | 9/20 | 0.44 |
| ▸ | CTSS | P25774 | 4/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501755 | 1.00 | ACE (0.46) | ACEPPARAPPARGCTSSCTSK | |
| SCHEMBL2581513 | 0.87 | CYP1A2 (0.48) | ACECTSSCTSKALDH1A1 | |
| SCHEMBL4521862 | 0.86 | ACE (0.46) | ACEPPARAPPARGCTSSCTSK | |
| SCHEMBL4521865 | 0.86 | ACE (0.46) | ACEPPARAPPARGCTSSCTSK | |
| SCHEMBL4521952 | 0.85 | PPARA (0.47) | ACEPPARAPPARGCTSSCTSK | |
| SCHEMBL4521942 | 0.85 | PPARA (0.47) | ACEPPARAPPARGCTSSCTSK | |
| SCHEMBL4337302 | 0.83 | ACE (0.46) | ACEPPARAPPARGCTSSCTSK | |
| SCHEMBL4504469 | 0.83 | PPARA (0.46) | ACEPPARAPPARGCTSSCTSK | |
| SCHEMBL4337305 | 0.83 | ACE (0.46) | ACEPPARAPPARGCTSSCTSK | |
| SCHEMBL4504464 | 0.83 | PPARA (0.46) | ACEPPARAPPARGCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953158-B1 | BICYCLIC CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | ACE 738/4885PPARA 1582/4885PPARG 2812/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | ACE 738/4885PPARA 1582/4885PPARG 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.